ReviewLupus science & medicine2015
Haematological manifestations of lupus.
Review in Lupus science & medicine, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 115 papers, 8 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
115 citing papers in PubMed, 8 syntheses or guidelines pooled it, 283 citations in OpenAlex.
- Thyroid dysfunction risk in systemic lupus erythematosus: a systematic review of case-control studies.Frontiers in immunology · 2026Pooled it
- Adrenal involvement in antiphospholipid syndrome and SLE-spectrum disease: a systematic review and pooled individual-patient analysis.Frontiers in immunology · 2026Pooled it
- Pooled it
- Immune thrombocytopenia in patients with systemic lupus erythematosus.Clinical rheumatology · 2025Pooled it
- Serum lipid profile in systemic lupus erythematosus.Frontiers in immunology · 2024Pooled it
- Essential Trace Element Status in Systemic Lupus Erythematosus: a Meta-analysis Based on Case-Control Studies.Biological trace element research · 2023Pooled it
- ANA-positive primary immune thrombocytopaenia: a different clinical entity with increased risk of connective tissue diseases.Lupus science & medicine · 2021Pooled it
- Lupus anticoagulant hypoprothrombinemia syndrome associated with systemic lupus erythematosus in children: report of two cases and systematic review of the literature.Rheumatology international · 2018Pooled it
- Autoantibody-positive healthy individuals with lower lupus risk display a unique immune endotype.The Journal of allergy and clinical immunology · 2020Trial
- Modelling pharmacokinetics and pharmacodynamics of the selective S1PBritish journal of clinical pharmacology · 2020Trial
- Early haematologic response to anifrolumab in SLE: results from the European multicentre EFFORT-SLE study.Rheumatology (Oxford, England) · 2026Article
- Can disease activity and treatment responses be captured by a core set of domains in SLE clinical trials? An analysis of phase III belimumab trial data.Lupus science & medicine · 2026Article
- Immune thrombocytopenia in patients with connective tissue disease.Clinical rheumatology · 2026Review
- Successful splenectomy for refractory systemic lupus erythematosus-associated autoimmune hemolytic anemia: a case report and mechanistic insight.Frontiers in immunology · 2026Article
- Article
- Establishment of a novel lupus mesenteric vasculitis mouse model and exploration of its exacerbation mechanisms.Frontiers in immunology · 2026Article
- Unmasking Evans Syndrome: A Case of New Onset Anemia and Thrombocytopenia in a Pregnant Patient With Systemic Lupus Erythematosus.Case reports in hematology · 2026Article
- Infectious Complications and Prognostic Factors of Mortality in Patients with Lupus Nephritis Admitted to Intensive Care Units.Journal of clinical medicine · 2025Article
- The Integrated Cellular and Molecular Landscape of Autoimmunity.bioRxiv : the preprint server for biology · 2025Article
- Rituximab as an Effective Treatment for New-onset Evans Syndrome and Systemic Lupus Erythematosus with Lupus Nephritis.Internal medicine (Tokyo, Japan) · 2025Article
55 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 5 institutions in 2 countries.
Funding
Abstract
Our purpose was to compile information on the haematological manifestations of systemic lupus erythematosus (SLE), namely leucopenia, lymphopenia, thrombocytopenia, autoimmune haemolytic anaemia (AIHA), thrombotic thrombocytopenic purpura (TTP) and myelofibrosis. During our search of the English-language MEDLINE sources, we did not place a date-of-publication constraint. Hence, we have reviewed previous as well as most recent studies with the subject heading SLE in combination with each manifestation. Neutropenia can lead to morbidity and mortality from increased susceptibility to infection. Severe neutropenia can be successfully treated with granulocyte colony-stimulating factor. While related to disease activity, there is no specific therapy for lymphopenia. Severe lymphopenia may require the use of prophylactic therapy to prevent select opportunistic infections. Isolated idiopathic thrombocytopenic purpura maybe the first manifestation of SLE by months or even years. Some manifestations of lupus occur more frequently in association with low platelet count in these patients, for example, neuropsychiatric manifestation, haemolytic anaemia, the antiphospholipid syndrome and renal disease. Thrombocytopenia can be regarded as an important prognostic indicator of survival in patients with SLE. Medical, surgical and biological treatment modalities are reviewed for this manifestation. First-line therapy remains glucocorticoids. Through our review, we conclude glucocorticoids do produce a response in majority of patients initially, but sustained response to therapy is unlikely. Glucocorticoids are used as first-line therapy in patients with SLE with AIHA, but there is no conclusive evidence to guide second-line therapy. Rituximab is promising in refractory and non-responding AIHA. TTP is not recognised as a criteria for classification of SLE, but there is a considerable overlap between the presenting features of TTP and SLE, and a few patients with SLE have concurrent TTP. Myelofibrosis is an uncommon yet well-documented manifestation of SLE. We have compiled the cases that were reported in MEDLINE sources.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.